Punicalagin Alleviates Psoriasis by Inhibiting NF-κB-Mediated IL-1β Transcription and Caspase-1-Regulated IL-1β Secretion

• DOI: 10.3389/fphar.2022.817526
• Publication Date: 2022-01-26T07:21:38Z
• Authors: Lipeng Tang; Tong Li; Bowen Zhang; Zihao Zhang; Xiaoyi Sun; Ying Zhu; Bing Feng; Zuqing Su; Laijun Yang; Hongxia Li; Huazhen Liu; Yuchao Chen; Zhenhua Dai; Xirun Zheng; Mingxian Li; Chutian Li; Jie Zhao; Xinmin Qiu; Shuyan Ye; Han Liu; Guangjuan Zheng; Ben Li; Chuanjian Lu
• Keywords: HaCaT; Imiquimod

Psoriasis is a chronic and inflammatory skin disorder characterized by inflammation epidermal hyperplasia. Punicalagin (PUN) main active ingredient of pomegranate (Punica granatum L.) peel with multiple biological activities, such as antibacterial, antioxidant anti-tumor effects. However, the potential effect PUN on psoriasis remains unknown. In this study, we want to investigate pharmacological using imiquimod (IMQ)-induced psoriatic mice model in vivo tumor necrosis factor (TNF-α) interleukin-17A (IL-17A)-stimulated HaCaT cells vitro. Our results showed that can effectively alleviate severity psoriasis-like symptoms. Mechanistically, potently suppresses aberrant upregulation interleukin-1β (IL-1β) subsequent IL-1β-mediated cascade keratinocytes inhibiting nuclear kappa B (NF-κB) activation cleaved caspase-1 expression vitro vivo. Taken together, our findings indicate relieve repressing NF-κB-mediated IL-1β transcription caspase-1-regulated secretion, which provide evidence might represent novel promising candidate for treatment psoriasis.